Form 4: CRISPR Therapeutics Director, John Greene, Acquires Stock Options
SEC Form 4 Filing
Director John Greene acquired stock options for 13,000 common shares in CRISPR Therapeutics, vesting monthly over the next year.
Summary
- John Greene, a director at CRISPR Therapeutics AG, was granted stock options on May 30, 2024.
- The options are for 13,000 common shares at an exercise price of $54.06.
- The options vest in 12 equal monthly installments starting May 31, 2024, with the final installment vesting by the earlier of the one-year anniversary of the grant date or the date of the 2025 Annual General Meeting of Shareholders.
Sentiment
Score: 6
Explanation: The document is a routine filing related to stock option grants, which is generally neutral. It indicates alignment of director's interests with shareholders.
Positives
- The granting of stock options to a director aligns their interests with those of the shareholders.
Industry Context
Stock options are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value.
Stakeholder Impact
- Shareholders may view the granting of stock options positively as it aligns the director's interests with the company's performance.
Key Dates
| Date | Description |
|---|---|
| 05/30/2024 | Date of the transaction: Stock options granted to John Greene. |
| 05/31/2024 | First vesting date for the stock options. |
| 05/30/2025 | One year anniversary of the grant date. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.